Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2)
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is an anti-mouse/human VLA-4/CD49d IgG2b monoclonal antibody. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can reduce VLA-4 positive cells. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can inhibit the migration of Tc1 cells to tumors. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) inhibits the retention of leukemia cells in the spleen and bone marrow by blocking VLA-4. Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) can be used for research on inflammation conditions and cancer such as experimental autoimmune encephalomyelitis (EAE), melanoma and leukemia.
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2b kappa
Human/Mouse
|
α4β1 |
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (20 μg/mL, 15 min) significantly inhibits the adhesion of Tc1 cells to VCAM-1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (150 μg, i.v., single dose) significantly inhibits the migration of Tc1 cells to intracranial tumors in C57BL/6 mice bearing M05 tumors[2].
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) (10 mg/kg, i.p., twice a week, for 5 weeks) significantly reduces tumor cells in the spleen and bone marrow in wild type C57BL/6J mice with a chronic lymphocytic leukemia (CLL) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×106 PFU SFV-A7 virus induced female BALB/c mice (6-8 weeks)[1]
-
Dosage:0.1 mg
-
Administration:Intraperitoneal injection (i.p.), once every other day, from day 4 to day 14
-
Result:Significantly reduced the incidence rate to 10 % and the average incidence day to 14.0 days.
Significantly reduced inflammation and some mouse brain tissues were completely free of inflammation.
Reduced VCAM-1 expression and decreased VLA-4 positive cells.
-
Animal Model:5×104 M05 cells injected C57BL/6 mice (5-9 weeks)[2]
-
Dosage:150 μg
-
Administration:Intravenous injection (i.v.), single dose
-
Result:Significantly inhibited the migration of Tc1 cells (inhibition of 85 %).
-
Animal Model:5×106 splenocytes from TCL1-tg mouse injected wild type C57BL/6J mice[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice a week, for 5 weeks
-
Result:Reduced the number of tumor cells in the spleen and bone marrow.
Reduced peripheral blood leukemia cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
in vivo VLA-4 neutralization; in vitro VLA-4 neutralization; Flow cytometry
-
Flow cytometric analysis of 1×106 Jurkat cells labelling VLA-4 (red) with Anti-Mouse/Human VLA-4 Antibody (HY-P990144). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Rabbit IgG H&L (AF488) (HY-P8002) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Rat IgG2b kappa Isotype Control (HY-P990682, blue) was used as the isotype control.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Soilu-Hänninen M, et al. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol. 1997 Jan;72(1):95-105. [Content Brief]
[2]. Sasaki K, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007 Jul 1;67(13):6451-8. [Content Brief]
[3]. Szenes E, et al. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia. 2020 Sep;34(9):2498-2502. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz